ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on May 27, 2025. The report addresses a notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing discloses the following specific financial metric derived from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025:
- Stockholders' Equity: $1,752,885
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the stockholders' equity figure.
Material Changes and Listing Status
The Company is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market. As of the report date, the Company's equity of $1,752,885 falls below this threshold.
Outlook, Management Commentary, and Risks
Compliance Timeline:
- Plan Submission Deadline: The Company has 45 calendar days (until July 11, 2025) to submit a plan to regain compliance.
- Compliance Period: If the plan is accepted, the Company may be granted up to 180 calendar days (until November 23, 2025) to evidence compliance.
Management Intent: The Company intends to take all reasonable measures to regain compliance and will submit a plan by the deadline. It is currently evaluating available options to resolve the deficiency.
Risks and Contingencies:
- There is no assurance that the compliance plan will be accepted by Nasdaq staff.
- There is no assurance the Company will be able to regain or maintain compliance with listing requirements.
- If the plan is rejected or compliance is not achieved, the Company has the right to a hearing before an independent panel, though success is not guaranteed.
- Failure to regain compliance could result in delisting.
Investor Verification Checklist
- Verify the Company's stockholders' equity balance as of March 31, 2025, in the Form 10-Q.
- Monitor the submission of the compliance plan by the July 11, 2025 deadline.
- Track the acceptance status of the compliance plan by Nasdaq staff.
- Review any subsequent filings regarding the Company's progress toward the $2,500,000 equity threshold.
- Assess the Company's capital raising activities or other strategies to address the equity deficiency.